NO328489B1 - Nye forbindelser og anvendelse av disse for fremstilling av farmasoytiske preparater for behandling av blant annet astma og diar± - Google Patents

Nye forbindelser og anvendelse av disse for fremstilling av farmasoytiske preparater for behandling av blant annet astma og diar± Download PDF

Info

Publication number: NO328489B1
Authority: NO; Norway
Prior art keywords: compound; preparation; compound according; pharmaceutical preparation; treatment
Prior art date: 1999-08-31

Application number

NO20020979A

Other languages

English (en)

Norwegian (no)

Other versions

NO20020979L (no

NO20020979D0 (no

Inventor

Italo O Biaggioni

Igor A Feoktistov

Jack N Wells

Original Assignee

Univ Vanderbilt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-31

Filing date

2002-02-27

Publication date

2010-03-01

2002-02-27 Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt

2002-02-27 Publication of NO20020979D0 publication Critical patent/NO20020979D0/no

2002-04-26 Publication of NO20020979L publication Critical patent/NO20020979L/no

2010-03-01 Publication of NO328489B1 publication Critical patent/NO328489B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 65
208000006673 asthma Diseases 0.000 title claims description 22
238000011282 treatment Methods 0.000 title claims description 22
239000000825 pharmaceutical preparation Substances 0.000 title claims description 18
238000004519 manufacturing process Methods 0.000 title claims description 8
206010012735 Diarrhoea Diseases 0.000 title claims description 6
238000002360 preparation method Methods 0.000 claims description 25
230000000694 effects Effects 0.000 claims description 24
150000003839 salts Chemical class 0.000 claims description 19
210000003630 histaminocyte Anatomy 0.000 claims description 14
230000002411 adverse Effects 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
206010040070 Septic Shock Diseases 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 8
230000012010 growth Effects 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
208000001132 Osteoporosis Diseases 0.000 claims description 6
208000018737 Parkinson disease Diseases 0.000 claims description 6
210000004204 blood vessel Anatomy 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
208000024827 Alzheimer disease Diseases 0.000 claims description 4
206010012289 Dementia Diseases 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
230000003915 cell function Effects 0.000 claims description 4
230000010261 cell growth Effects 0.000 claims description 4
208000035475 disorder Diseases 0.000 claims description 4
208000019622 heart disease Diseases 0.000 claims description 4
208000027866 inflammatory disease Diseases 0.000 claims description 4
230000002757 inflammatory effect Effects 0.000 claims description 4
230000003871 intestinal function Effects 0.000 claims description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
206010006895 Cachexia Diseases 0.000 claims description 3
206010063094 Cerebral malaria Diseases 0.000 claims description 3
201000009273 Endometriosis Diseases 0.000 claims description 3
206010014824 Endotoxic shock Diseases 0.000 claims description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 3
208000032456 Hemorrhagic Shock Diseases 0.000 claims description 3
102100020873 Interleukin-2 Human genes 0.000 claims description 3
108010002350 Interleukin-2 Proteins 0.000 claims description 3
206010027202 Meningitis bacterial Diseases 0.000 claims description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
206010040047 Sepsis Diseases 0.000 claims description 3
206010049771 Shock haemorrhagic Diseases 0.000 claims description 3
206010044248 Toxic shock syndrome Diseases 0.000 claims description 3
231100000650 Toxic shock syndrome Toxicity 0.000 claims description 3
206010052779 Transplant rejections Diseases 0.000 claims description 3
208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
206010003246 arthritis Diseases 0.000 claims description 3
201000009904 bacterial meningitis Diseases 0.000 claims description 3
210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
230000036512 infertility Effects 0.000 claims description 3
230000005764 inhibitory process Effects 0.000 claims description 3
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
201000006417 multiple sclerosis Diseases 0.000 claims description 3
210000000056 organ Anatomy 0.000 claims description 3
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
230000010076 replication Effects 0.000 claims description 3
230000036303 septic shock Effects 0.000 claims description 3
230000035939 shock Effects 0.000 claims description 3
210000002460 smooth muscle Anatomy 0.000 claims description 3
230000009529 traumatic brain injury Effects 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims 2
239000000969 carrier Substances 0.000 claims 2
239000000428 dust Substances 0.000 claims 2
239000000446 fuel Substances 0.000 claims 2
125000004193 piperazinyl group Chemical group 0.000 claims 1
101150078577 Adora2b gene Proteins 0.000 description 27
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 20
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 14
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 13
239000002126 C01EB10 - Adenosine Substances 0.000 description 12
229960005305 adenosine Drugs 0.000 description 12
239000003814 drug Substances 0.000 description 12
239000005557 antagonist Substances 0.000 description 11
-1 carboxymethoxy substituent Chemical group 0.000 description 11
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
229940124597 therapeutic agent Drugs 0.000 description 9
108050000203 Adenosine receptors Proteins 0.000 description 8
102000009346 Adenosine receptors Human genes 0.000 description 8
239000002775 capsule Substances 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
230000003389 potentiating effect Effects 0.000 description 8
239000003826 tablet Substances 0.000 description 8
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 7
239000000203 mixture Substances 0.000 description 7
239000000296 purinergic P1 receptor antagonist Substances 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
229940121359 adenosine receptor antagonist Drugs 0.000 description 6
239000000556 agonist Substances 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
229960000278 theophylline Drugs 0.000 description 6
230000004913 activation Effects 0.000 description 5
239000000924 antiasthmatic agent Substances 0.000 description 5
230000020411 cell activation Effects 0.000 description 5
QVDKSPUZWYTNQA-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=NC=N[C]21 QVDKSPUZWYTNQA-UHFFFAOYSA-N 0.000 description 5
229950000579 enprofylline Drugs 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
230000024883 vasodilation Effects 0.000 description 5
IWALGNIFYOBRKC-UHFFFAOYSA-N 4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)benzenesulfonic acid Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(S(O)(=O)=O)C=C1 IWALGNIFYOBRKC-UHFFFAOYSA-N 0.000 description 4
101150051188 Adora2a gene Proteins 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
206010047141 Vasodilatation Diseases 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
229960004793 sucrose Drugs 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108010041368 Adenosine A2 Receptors Proteins 0.000 description 3
102000000506 Adenosine A2 Receptors Human genes 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
102000030621 adenylate cyclase Human genes 0.000 description 3
108060000200 adenylate cyclase Proteins 0.000 description 3
150000001735 carboxylic acids Chemical class 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229910003460 diamond Inorganic materials 0.000 description 3
239000010432 diamond Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000012669 liquid formulation Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000035790 physiological processes and functions Effects 0.000 description 3
239000006187 pill Substances 0.000 description 3
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
206010006482 Bronchospasm Diseases 0.000 description 2
241000282465 Canis Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
102000043136 MAP kinase family Human genes 0.000 description 2
108091054455 MAP kinase family Proteins 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
244000246386 Mentha pulegium Species 0.000 description 2
235000016257 Mentha pulegium Nutrition 0.000 description 2
235000004357 Mentha x piperita Nutrition 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
239000004044 bronchoconstricting agent Substances 0.000 description 2
230000002741 bronchospastic effect Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
235000001050 hortel pimenta Nutrition 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
201000006512 mast cell neoplasm Diseases 0.000 description 2
208000006971 mastocytoma Diseases 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
230000021014 regulation of cell growth Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000005556 structure-activity relationship Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 2
PAJRLOFUBZXVOC-UHFFFAOYSA-N 1-(1,5-dipropylcyclohexa-2,4-dien-1-yl)-2,6-dioxo-3,7-dihydropurine-8-sulfonic acid Chemical compound C1C(CCC)=CC=CC1(CCC)N1C(=O)C(NC(=N2)S(O)(=O)=O)=C2NC1=O PAJRLOFUBZXVOC-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
MHUQGIMGNNMPLF-UHFFFAOYSA-N 8-(1,5-diethylcyclohexa-2,4-dien-1-yl)-3,7-dihydropurine-2,6-dione Chemical compound C(C)C1(CC(=CC=C1)CC)C1=NC=2NC(NC(C=2N1)=O)=O MHUQGIMGNNMPLF-UHFFFAOYSA-N 0.000 description 1
JCAIYNMCEMWPAD-UHFFFAOYSA-N 8-bromo-1-methyl-3-(2-methylpropyl)-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1NC(Br)=N2 JCAIYNMCEMWPAD-UHFFFAOYSA-N 0.000 description 1
229940124049 Adenosine A2 receptor antagonist Drugs 0.000 description 1
102000007470 Adenosine A2B Receptor Human genes 0.000 description 1
108010085273 Adenosine A2B receptor Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000004135 Bone phosphate Substances 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
FFBDFADSZUINTG-UHFFFAOYSA-N DPCPX Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1CCCC1 FFBDFADSZUINTG-UHFFFAOYSA-N 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
235000016623 Fragaria vesca Nutrition 0.000 description 1
240000009088 Fragaria x ananassa Species 0.000 description 1
235000011363 Fragaria x ananassa Nutrition 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108091006068 Gq proteins Proteins 0.000 description 1
102000052606 Gq-G11 GTP-Binding Protein alpha Subunits Human genes 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
102000011195 Profilin Human genes 0.000 description 1
108050001408 Profilin Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000001400 Tryptase Human genes 0.000 description 1
108060005989 Tryptase Proteins 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
208000032594 Vascular Remodeling Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
239000003449 adenosine A2 receptor antagonist Substances 0.000 description 1
150000003838 adenosines Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
RWLDAJMGAVDXSH-UHFFFAOYSA-N ethane-1,1,2-tricarboxylic acid Chemical compound OC(=O)CC(C(O)=O)C(O)=O RWLDAJMGAVDXSH-UHFFFAOYSA-N 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000036737 immune function Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000002490 intestinal epithelial cell Anatomy 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
230000006525 intracellular process Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical group CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
230000004088 pulmonary circulation Effects 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000011160 research Methods 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000000523 sample Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Psychology (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)

NO20020979A 1999-08-31 2002-02-27 Nye forbindelser og anvendelse av disse for fremstilling av farmasoytiske preparater for behandling av blant annet astma og diar± NO328489B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15164999P	1999-08-31	1999-08-31
PCT/US2000/040751 WO2001016134A1 (en)	1999-08-31	2000-08-28	Selective antagonists of a2b adenosine receptors

Publications (3)

Publication Number	Publication Date
NO20020979D0 NO20020979D0 (no)	2002-02-27
NO20020979L NO20020979L (no)	2002-04-26
NO328489B1 true NO328489B1 (no)	2010-03-01

Family

ID=22539669

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20020979A NO328489B1 (no)	1999-08-31	2002-02-27	Nye forbindelser og anvendelse av disse for fremstilling av farmasoytiske preparater for behandling av blant annet astma og diar±

Country Status (22)

Country	Link
EP (1)	EP1208100B1 (es)
JP (1)	JP3914434B2 (es)
KR (1)	KR100502757B1 (es)
CN (1)	CN1178940C (es)
AR (1)	AR029178A1 (es)
AT (1)	ATE236160T1 (es)
AU (1)	AU760071B2 (es)
BR (1)	BR0013673A (es)
CA (1)	CA2383351C (es)
DE (1)	DE60001969T2 (es)
DK (1)	DK1208100T3 (es)
ES (1)	ES2190422T3 (es)
HK (1)	HK1049835B (es)
IL (2)	IL148366A0 (es)
MX (1)	MXPA02002262A (es)
NO (1)	NO328489B1 (es)
NZ (1)	NZ517546A (es)
PT (1)	PT1208100E (es)
TR (1)	TR200201132T2 (es)
TW (1)	TWI262921B (es)
WO (1)	WO2001016134A1 (es)
ZA (1)	ZA200201650B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6403567B1 (en)	1999-06-22	2002-06-11	Cv Therapeutics, Inc.	N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en)	1999-06-22	2019-04-16	Gilead Sciences, Inc.	2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US20020012946A1 (en)	2000-02-23	2002-01-31	Luiz Belardinelli	Method of identifying partial agonists of the A2A receptor
EP1401837B1 (en) *	2001-06-29	2005-10-19	Cv Therapeutics, Inc.	Purine derivatives as a2b adenosine receptor antagonists
US8470801B2 (en)	2002-07-29	2013-06-25	Gilead Sciences, Inc.	Myocardial perfusion imaging methods and compositions
EP1646390B1 (en) *	2003-07-22	2008-10-08	Cv Therapeutics, Inc.	A1 adenosine receptor antagonists
JPWO2005053695A1 (ja) *	2003-12-04	2007-12-06	エーザイ・アール・アンド・ディー・マネジメント株式会社	多発性硬化症予防剤または治療剤
EP1781657B1 (en) *	2004-02-14	2013-03-27	GlaxoSmithKline Intellectual Property Development Limited	Medicaments with hm74a receptor activity
JP2008516969A (ja) *	2004-10-15	2008-05-22	シーブイ・セラピューティクス・インコーポレイテッド	Ａ２ｂアデノシン受容体アンタゴニストを使用した、気道のリモデリングおよび肺の炎症の予防および処置の方法
CN101076343A (zh)	2004-10-20	2007-11-21	Cv医药有限公司	A2a腺苷受体激动剂的应用
ES2270715B1 (es)	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
ES2274712B1 (es)	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
ES2273599B1 (es)	2005-10-14	2008-06-01	Universidad De Barcelona	Compuestos para el tratamiento de la fibrilacion auricular.
CN102260311A (zh)	2006-02-03	2011-11-30	吉利德帕洛阿尔托股份有限公司	制备一种a2a型腺苷受体激动剂及其多晶形物的方法
WO2007095161A2 (en) *	2006-02-14	2007-08-23	New York University	Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
DE102011005232A1 (de)	2011-03-08	2012-09-13	AristoCon GmbH & Co. KG	Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
US11370792B2 (en)	2015-12-14	2022-06-28	Raze Therapeutics, Inc.	Caffeine inhibitors of MTHFD2 and uses thereof
BR112021012685A2 (pt)	2019-01-11	2021-12-28	Omeros Corp	Métodos para tratar câncer, para aumentar o nível de citocinas th1 nas células mononucleares de sangue periférico humanas, para realçar uma resposta imune antitumoral e para estimular e/ou amplificar uma resposta imune em um sujeito mamífero sofrendo de ou em risco de desenvolver câncer ou metástase de câncer, e, composição farmacêutica

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7810946L (sv) *	1978-10-20	1980-04-21	Draco Ab	Metod att behandla kronisk obstruktiv luftvegssjukdom
DE4019892A1 (de) *	1990-06-22	1992-01-02	Boehringer Ingelheim Kg	Neue xanthinderivate
KR930703319A (ko) *	1990-12-21	1993-11-29	데이빗 로버츠	키산틴 유도체
GB9210839D0 (en) *	1992-05-21	1992-07-08	Smithkline Beecham Plc	Novel compounds

2000
- 2000-08-28 HK HK03101920.0A patent/HK1049835B/zh not_active IP Right Cessation
- 2000-08-28 AT AT00971055T patent/ATE236160T1/de not_active IP Right Cessation
- 2000-08-28 BR BR0013673-5A patent/BR0013673A/pt not_active Application Discontinuation
- 2000-08-28 ES ES00971055T patent/ES2190422T3/es not_active Expired - Lifetime
- 2000-08-28 JP JP2001519700A patent/JP3914434B2/ja not_active Expired - Fee Related
- 2000-08-28 PT PT00971055T patent/PT1208100E/pt unknown
- 2000-08-28 EP EP00971055A patent/EP1208100B1/en not_active Expired - Lifetime
- 2000-08-28 DK DK00971055T patent/DK1208100T3/da active
- 2000-08-28 MX MXPA02002262A patent/MXPA02002262A/es active IP Right Grant
- 2000-08-28 KR KR10-2002-7002718A patent/KR100502757B1/ko not_active Expired - Fee Related
- 2000-08-28 TR TR2002/01132T patent/TR200201132T2/xx unknown
- 2000-08-28 NZ NZ517546A patent/NZ517546A/en unknown
- 2000-08-28 DE DE60001969T patent/DE60001969T2/de not_active Expired - Lifetime
- 2000-08-28 CA CA002383351A patent/CA2383351C/en not_active Expired - Fee Related
- 2000-08-28 WO PCT/US2000/040751 patent/WO2001016134A1/en not_active Ceased
- 2000-08-28 IL IL14836600A patent/IL148366A0/xx active IP Right Grant
- 2000-08-28 CN CNB00813717XA patent/CN1178940C/zh not_active Expired - Fee Related
- 2000-08-28 AU AU80348/00A patent/AU760071B2/en not_active Ceased
- 2000-08-30 AR ARP000104523A patent/AR029178A1/es active IP Right Grant
- 2000-09-21 TW TW089117772A patent/TWI262921B/zh not_active IP Right Cessation
2002
- 2002-02-25 IL IL148366A patent/IL148366A/en not_active IP Right Cessation
- 2002-02-27 NO NO20020979A patent/NO328489B1/no not_active IP Right Cessation
- 2002-02-27 ZA ZA200201650A patent/ZA200201650B/en unknown

Also Published As

Publication number	Publication date
HK1049835B (zh)	2005-04-08
CN1377352A (zh)	2002-10-30
AU8034800A (en)	2001-03-26
ES2190422T3 (es)	2003-08-01
CN1178940C (zh)	2004-12-08
PT1208100E (pt)	2003-07-31
KR20020041419A (ko)	2002-06-01
JP3914434B2 (ja)	2007-05-16
EP1208100A1 (en)	2002-05-29
JP2003508398A (ja)	2003-03-04
MXPA02002262A (es)	2002-09-30
EP1208100B1 (en)	2003-04-02
DE60001969T2 (de)	2004-02-05
TR200201132T2 (tr)	2002-08-21
WO2001016134A1 (en)	2001-03-08
ATE236160T1 (de)	2003-04-15
NO20020979L (no)	2002-04-26
ZA200201650B (en)	2003-05-28
DE60001969D1 (de)	2003-05-08
HK1049835A1 (en)	2003-05-30
DK1208100T3 (da)	2003-06-30
AR029178A1 (es)	2003-06-18
AU760071B2 (en)	2003-05-08
CA2383351C (en)	2005-11-01
NO20020979D0 (no)	2002-02-27
NZ517546A (en)	2003-10-31
TWI262921B (en)	2006-10-01
KR100502757B1 (ko)	2005-07-22
IL148366A0 (en)	2002-09-12
BR0013673A (pt)	2002-05-28
CA2383351A1 (en)	2001-03-08
IL148366A (en)	2006-12-10

Publication	Publication Date	Title
NO328489B1 (no)	2010-03-01	Nye forbindelser og anvendelse av disse for fremstilling av farmasoytiske preparater for behandling av blant annet astma og diar±
US7335655B2 (en)	2008-02-26	8-heteroaryl xanthine adenosine A2B receptor antagonists
Feoktistov et al.	2001	Inhibition of human mast cell activation with the novel selective adenosine A2B receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)
MX2008011828A (es)	2008-09-29	Metodo para la prevencion y el tratamiento de enfermedad hepatica utilizando antagonistas del receptor de adenosina a2b.
HU180219B (en)	1983-02-28	Process for producing substituted xantine derivatives and salts
EP1347981B1 (en)	2008-05-07	Condensed purine derivatives as a 1 adenosine receptor antagonists
US6815446B1 (en)	2004-11-09	Selective antagonists of A2B adenosine receptors
ES2260061T3 (es)	2006-11-01	Composiciones farmaceuticas para trastornos relacionados con la alimentacion.
CA2554426C (en)	2012-10-16	Agents for treating migraine
WO1999030715A1 (en)	1999-06-24	Preventives/remedies for sleep disturbance
AU4875197A (en)	1998-05-29	Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis
LU83849A1 (en)	1982-05-07	PROCESS FOR THE PREPARATION OF XANTHINE DERIVATIVES

Legal Events

Date	Code	Title	Description
2011-04-04	MM1K	Lapsed by not paying the annual fees